Dr. Duggan completed his medical undergraduate and internal medicine residency at the Memorial University of Newfoundland. He subsequently completed Hematology and Bone Marrow Transplant Fellowships at the University of Calgary. He has held a number of leadership positions within the AHS Calgary Zone (Hematology Tumor Group Lead, Medical Director of the Cellular Therapy Laboratory, Head of the Section of Hematology and Interim Chief, Department of Oncology). He currently directs the Advanced Oncology Fellowship in Multiple Myeloma and Plasma Cell Disorders.
Biography
Area of Focus
Summary of Research
Dr. Duggan is a Clinical Associate Professor in the Departments of Medicine and Oncology at Cuming School of Medicine/University of Calgary. His clinical and research interests are in lymphoma, plasma cell disorders and autologous hematopoietic cell transplantation. Recent publications include the following:
- Lee H, Tay J, Duggan P, McCulloch S, Neri P, Bahlis NJ, Jimenez-Zepeda VH. The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience. Eur J Haematol. 2020 Nov 16.
- Pham TM, Shen-Tu G, Nguyen KH, Lu S, Dover DC, Duggan P, Shack L, Cheung WY. Premature Mortality due to Hodgkin’s Lymphoma, Non-Hodgkin’s Lymphoma, Multiple Myeloma, and Leukemia in Canada: A Nationwide Analysis from 1980 to 2015. Am J Epidemiol. 2020 Jul 24
- Ousia S, Kalra A, Williamson TS, Prokopishyn N, Dharmani-Khan P, Khan FM, Jimenez-Zepeda V, Jamani K, Duggan PR, Daly A, Russell JA, Storek J. Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low-dose total body irradiation, and rabbit antithymocyte globulin. Clin Transplant. 2020 Jun 23:e14018.
Area Of Focus
Summary Of Research
Dr. Duggan is a Clinical Associate Professor in the Departments of Medicine and Oncology at Cuming School of Medicine/University of Calgary. His clinical and research interests are in lymphoma, plasma cell disorders and autologous hematopoietic cell transplantation. Recent publications include the following:
- Lee H, Tay J, Duggan P, McCulloch S, Neri P, Bahlis NJ, Jimenez-Zepeda VH. The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience. Eur J Haematol. 2020 Nov 16.
- Pham TM, Shen-Tu G, Nguyen KH, Lu S, Dover DC, Duggan P, Shack L, Cheung WY. Premature Mortality due to Hodgkin’s Lymphoma, Non-Hodgkin’s Lymphoma, Multiple Myeloma, and Leukemia in Canada: A Nationwide Analysis from 1980 to 2015. Am J Epidemiol. 2020 Jul 24
- Ousia S, Kalra A, Williamson TS, Prokopishyn N, Dharmani-Khan P, Khan FM, Jimenez-Zepeda V, Jamani K, Duggan PR, Daly A, Russell JA, Storek J. Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low-dose total body irradiation, and rabbit antithymocyte globulin. Clin Transplant. 2020 Jun 23:e14018.